BAĞCI, B. Et Al. 2016. KRAS, BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2, DAPK1, MGMT, HIC1 and p16 genes in colorectal cancer patients. CANCER BIOMARKERS , vol.17, no.2 , 133-143.

BAĞCI, B., SARİ, M., KARADAYI, K., TURAN, M., ÖZDEMİR, Ö., & BAĞCI, G., (2016). KRAS, BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2, DAPK1, MGMT, HIC1 and p16 genes in colorectal cancer patients. CANCER BIOMARKERS , vol.17, no.2, 133-143.

BAĞCI, BİNNUR Et Al. "KRAS, BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2, DAPK1, MGMT, HIC1 and p16 genes in colorectal cancer patients," CANCER BIOMARKERS , vol.17, no.2, 133-143, 2016

BAĞCI, BİNNUR Et Al. "KRAS, BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2, DAPK1, MGMT, HIC1 and p16 genes in colorectal cancer patients." CANCER BIOMARKERS , vol.17, no.2, pp.133-143, 2016

BAĞCI, B. Et Al. (2016) . "KRAS, BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2, DAPK1, MGMT, HIC1 and p16 genes in colorectal cancer patients." CANCER BIOMARKERS , vol.17, no.2, pp.133-143.

@article{article, author={BİNNUR BAĞCI Et Al. }, title={KRAS, BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2, DAPK1, MGMT, HIC1 and p16 genes in colorectal cancer patients}, journal={CANCER BIOMARKERS}, year=2016, pages={133-143} }